Patent infringement

Search documents
Alpha Modus Ventures Files Patent Infringement Lawsuit Against Cisco Systems
Globenewswire· 2025-06-11 12:00
Core Viewpoint - Alpha Modus Ventures, LLC has filed a patent infringement lawsuit against Cisco Systems, Inc. for allegedly infringing three patents related to Fibre Channel over Ethernet technology [1][2]. Group 1: Lawsuit Details - The lawsuit was filed in the U.S. District Court for the Western District of Texas on June 9, 2025, and claims that Cisco's products, including its Unified Computing System and Converged Network Adapters, infringe on U.S. Patent Nos. 11,108,591, 11,310,077, and 11,303,473 [1][2]. - AMV is seeking monetary damages for Cisco's past use of the patented technology, asserting that Cisco's unauthorized use has led to significant commercial benefits at the expense of AMV's proprietary rights [3]. Group 2: Company Statements - Alpha Modus CEO William Alessi emphasized the company's commitment to protecting its intellectual property rights and stated that shareholders deserve recognition and compensation for the unauthorized use of their innovations [4].
How a decade-old patent dispute could upend Uber's business
TechCrunch· 2025-05-30 17:00
Core Viewpoint - A patent infringement lawsuit filed by Carma Technology against Uber could have significant implications for Uber and potentially other companies in the ride-sharing industry [1][2]. Company Overview - Carma Technology, founded in 2007 by Sean O'Sullivan, has accused Uber of infringing on five patents related to matching riders with vehicle capacity, a core aspect of ride-sharing [2][3]. - The lawsuit seeks a jury trial, a permanent injunction against Uber, mandatory future royalties, damages, and other costs [3]. Legal Background - Carma first contacted Uber regarding its patents in 2016, during a period when Uber was valued at $66 billion and expanding rapidly [4][5]. - Uber was aware of Carma's patents as early as 2015 when a patent application was rejected due to existing patents held by Carma [6][8]. - Between 2016 and 2019, several of Uber's patent applications were rejected for similar reasons, leading to the abandonment of some applications [8]. Patent Details - The five patents in question are part of a larger family of 30 patents that Carma has developed over 18 years, with each patent containing multiple claims [10][11]. - The first patent, granted in 2010, established a shared transport system that matches empty vehicle space with riders or goods [17][18]. Business Model Shift - Carma initially focused on ride-sharing but shifted its business model to road-pricing services like GPS tolling and HOV verification by 2018 [20][23]. - The company aims to help transit authorities manage tolls and express lanes, promoting carpooling and reducing traffic congestion [22][23]. Financial Implications - Carma is currently profitable, but pursuing the lawsuit will impact its bottom line [24]. - The lawsuit is seen as a necessary step to protect the rights of inventors against larger companies that may infringe on patents [25][26].
泽井集团:日本医疗保健行业:制药领域:初步观点:泽井制药在专利侵权纠纷中被判向东丽支付赔偿金-20250528
Goldman Sachs· 2025-05-28 05:10
Investment Rating - Sawai Group is rated as "Sell" with a 12-month target price of ¥1,650 [2][14] - Toray is rated as "Buy" with a 12-month target price of ¥1,300 [3][15] Core Insights - The Intellectual Property High Court (IPHC) has ordered Sawai Pharmaceutical to pay ¥14.3 billion in damages for patent infringement related to the pruritus treatment Remitch [1][8] - The ruling is expected to negatively impact Sawai Group's share price due to the realization of compensation payment risks and potential strategic implications for its market share growth [2][12] - For Toray, the ruling is seen as a significant win for its intellectual property strategy, potentially leading to a positive impact on its profit and cash flow if compensation is received [3][11] Summary by Sections Sawai Group - The company plans to restate its FY3/25 earnings due to the ruling, with the impact on earnings currently being assessed [8] - Sawai intends to appeal the ruling and is considering all legal measures [8][9] - The ruling may affect Sawai's strategy of increasing market share through its intellectual property and drug formulation technology [12] Toray - The total compensation ordered against Sawai and Fuso Pharmaceutical amounts to ¥21.7 billion, with Toray potentially receiving ¥21.7 billion [11] - The ruling reinforces the strength of Toray's intellectual property strategy and could lead to a considerable impact on its earnings, given its projected net profits of ¥82 billion for FY3/26 [11]